• Twitter
  • Jobs
ProCURE oncology
  • HOME
  • ABOUT US
  • RESEARCH GROUP
    • Molleví’s Lab
    • Antolin’s Lab
    • Alemany’s & Piulats’s lab
    • Martínez-Balibrea’s Lab
    • Aytes’s Lab
    • Belver’s Lab
    • Pujana’s Lab
    • Menendez’s Lab
    • Sureda’s & Farre’s Lab
    • Casanovas’s Lab
    • Viñals’s lab
  • INNOVATION
  • NEWS
  • CONTACT
  • Menu Menu
VIEW ALL RESEARCH-GROUP

Tumor microenvironment and resistance
Molleví’s Lab

DESCRIPTION

The research group studies the influence of microenvironment, and particularly carcinoma-associated fibroblasts (CAFs) on tumorigenesis and therapy resistance in highly desmoplastic tumors, mainly colorectal hepatic metastases.

The research group studies the influence of the microenvironment on carcinogenesis in highly desmoplastic tumors, mainly liver metastases from colorectal cancer, since in these tumors cells from the microenvironment play a decisive role in the formation of the characteristic histological growth patterns (HGP) of these malignant lesions, and consequently, in the prognosis of the disease. In addition, the acquisition of resistant phenotypes has also been associated with a particular HGP.

What is desmoplasia? Desmoplasia is a histological feature characterized by an increase in the production of specific collagens, fibronectin, glycosaminoglycans, proteoglycans and other components of the extracellular matrix, as well as a deregulated increase in the number of mesenchymal cells, especially carcinoma-associated fibroblasts (CAFs). In hepatic malignancies, CAFs can come from different cell types, e.g. portal fibroblasts, hepatic stellate cells, vascular smooth muscle cells, pericytes, among others. Likewise, the contribution of each of them to the tumor stroma is variable depending on the type of malignant neoplasm, and interestingly, depending on the place of establishment of the tumor niche, particularly in liver metastases. Furthermore, each of these cell types will maintain a transcriptional program specific to its origin, a fact that leads to an increase in the functional heterogeneity of these cells. This is decisive if we consider CAFs as potential therapeutic targets. Therefore, it is necessary to clearly distinguish those CAFs with pro-tumor properties from those that act in favor of the host, called restrictive or anti-tumor CAFs. And this is a long path still to be walked.

Therefore, the main research interests of the group are:

  • To decipher the contribution and function of the different CAF precursors in liver malignancies and particularly on the different types of HGP in liver metastases.
  • Reprogramming specific CAFs as therapeutic strategy in desmoplastic tumors 
  • Discovery of stromal biomarkers for response prediction to neoadjuvant treatment in hepatic metastases from colorectal carcinoma.
  • Predicting the histologic growth pattern of liver metastases.

Group members

David G. Molleví

Group leaders

IP

Natalia Molina

PhD student

Predoctoral researcher

María Bañuls

Laboratory technician

Laboratory technician

Núria Ruiz

Clinical researcher

Clinical collaborator

Kristel Mils

Clinical researcher

Clinical collaborator

Laura Lladó

Clinical researcher

Clinical collaborator

Publications

Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment

1 de April de 2006/in Molleví's Lab/by miguel

J Clin Oncol. 2006 Apr 1;24(10):1603-11. doi: 10.1200/JCO.2005.03.5253. ABSTRACT PURPOSE: The purpose of this study was to analyze the value of germline and tumor thymidylate synthase (TS) genotyping as a prognostic marker in a series of colorectal cancer patients receiving adjuvant fluorouracil (FU) -based treatment. PATIENTS AND METHODS: One hundred twenty-nine colorectal cancer patients homogeneously […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2006-04-01 11:00:002006-04-01 11:00:00Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment

Modulation of the pathology of late xenograft rejection by PAF-antagonist UR-12670 in the hamster-to-rat liver xenotransplant model

20 de May de 2003/in Molleví's Lab/by miguel

APMIS. 2003 Mar;111(3):371-81. doi: 10.1034/j.1600-0463.2003.t01-1-1110201.x. ABSTRACT PAF antagonists have been used in xenotransplantation to alleviate the pathogenesis of hyperacute rejection. This study evaluated the ability of the PAF antagonist UR-12670 to improve graft function in late xenograft rejection (LXR) in an orthotopic liver xenotransplantation model, and the involvement of PAF (platelet activating factor) in this […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2003-05-20 10:00:002003-05-20 10:00:00Modulation of the pathology of late xenograft rejection by PAF-antagonist UR-12670 in the hamster-to-rat liver xenotransplant model

Acute xenograft rejection, late xenograft rejection and long term survival xenografts in the hamster-to-rat heart transplantation model: histological characterisation under low-dose of FK506

14 de February de 2003/in Molleví's Lab/by miguel

APMIS. 2002 Oct;110(10):737-45. doi: 10.1034/j.1600-0463.2002.1101008.x. ABSTRACT BACKGROUND: Long-term survival studies have been conducted in hamster-to-rat cardiac models with a range of immunosuppressive treatments, but the histological pattern of Late Xenograft Rejection (LXR) has not been outlined. This study offers a detailed description of the histological changes in cardiac xenografts under three different immunological responses. MATERIALS […]

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2003-02-14 11:00:002003-02-14 11:00:00Acute xenograft rejection, late xenograft rejection and long term survival xenografts in the hamster-to-rat heart transplantation model: histological characterisation under low-dose of FK506

Histology and immunopathology of heart and liver xenografts under low-dose tacrolimus

18 de April de 2002/in Molleví's Lab/by miguel

Transplant Proc. 2002 Feb;34(1):317-8. doi: 10.1016/s0041-1345(01)02781-6. NO ABSTRACT PMID:11959305 | DOI:10.1016/s0041-1345(01)02781-6

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2002-04-18 10:00:002002-04-18 10:00:00Histology and immunopathology of heart and liver xenografts under low-dose tacrolimus

Late xenograft rejection: comparison between liver and heart xenografts under low-dose tacrolimus

18 de April de 2002/in Molleví's Lab/by miguel

Transplant Proc. 2002 Feb;34(1):111-2. doi: 10.1016/s0041-1345(01)02693-8. NO ABSTRACT PMID:11959212 | DOI:10.1016/s0041-1345(01)02693-8

https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg 0 0 miguel https://procure-oncology.com/wp-content/uploads/2023/10/Procure-icoRecurso-1@2x-100.jpg miguel2002-04-18 10:00:002002-04-18 10:00:00Late xenograft rejection: comparison between liver and heart xenografts under low-dose tacrolimus
Page 6 of 7«‹4567›

Collaborations

Peter B. Vermeulen, University of Antwerp and GZA Hospitals, Belgium
Artur Mezheyeuski, VHIO, Barcelona
Pnina Brodt, Mc Gill University, Montreal, Canada
and Liver Metastases Research Network members

Molleví’s Lab
Program Against Cancer Therapeutic Resistance

CONTACT US

Campus IDIBELL
(L’Hospitalet del Llobregat)
Hospital Duran i Reynals, Gran Via 199,
L’Hospitalet del Llobregat,
Barcelona 08908
Tel. +34 93 260 7952

Campus IGTP-IJC
(Badalona)
Campus Can Ruti – IGTP – Building Muntanya,
Rd. Can Ruti, Camí de les escoles s/n,
Badalona, Barcelona 08916
Tel. +34 93 554 3069

Campus IDIBGI
(Girona)
Parc Hospitalari Martí i Julià de Salt, Dr. Castany s/n,
Salt, Girona 17190
Tel. +34 872 987 087

© Copyright - Edisenius
  • Privacy Policy
  • Cookie Policy
  • Legal Notice
Antolin's LabAntolin’s Lab
Scroll to top
Manage cookie consent
To offer the best experiences, we use technologies such as cookies to store and/or access device information. Consent to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Failure to consent, or withdrawal of consent, may adversely affect certain features and functions.
Functional Always active
Storage or technical access is strictly necessary for the legitimate purpose of allowing the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. Storage or technical access that is used exclusively for anonymous statistical purposes. Without a requirement, voluntary compliance by your Internet service provider, or additional records from a third party, information stored or retrieved solely for this purpose cannot be used to identify you.
Marketing
Storage or technical access is necessary to create user profiles to send advertising, or to track the user on a website or several websites for similar marketing purposes.
Manage options Manage services Manage {vendor_count} vendors Read more about these purposes
See preferences
{title} {title} {title}